📊 HAE Key Takeaways
Is Haemonetics Corp. (HAE) a Good Investment?
Haemonetics faces material operational challenges with revenue stagnation and 42% net income decline YoY, offset partially by strong free cash flow generation and solid liquidity. Elevated debt levels (1.56x debt/equity) compound the risk profile given deteriorating profitability, suggesting the company requires near-term operational improvement to justify holding.
Haemonetics shows strong profitability and cash generation, with nearly 60% gross margin, 18% operating margin, and a robust 21% free cash flow margin supporting a moderate-leverage balance sheet. EPS growth outpaced flat revenue on margin expansion and cost discipline; sustaining efficiency while reaccelerating top-line growth is the swing factor. Solid liquidity and free cash flow provide room to delever and invest, warranting a constructive view despite growth stagnation.
Haemonetics Corp. Key Strengths (HAE)
- Exceptional free cash flow of $260.4M with 19.5% FCF margin demonstrates underlying business strength
- Strong liquidity position with 2.95x current ratio and $245.4M cash buffer
- Healthy gross margin of 59% and robust operating cash flow of $293.2M indicate core operations remain productive
- Interest coverage of 8.1x shows current ability to service debt obligations
- High margins with strong FCF conversion (21% FCF margin)
- EPS up 44.5% YoY on operating leverage and cost control
- Adequate liquidity (1.75x current, 1.15x quick) supporting flexibility
HAE Stock Risks: Haemonetics Corp. Investment Risks
- Revenue stagnation at 0% YoY growth signals loss of market momentum in medical devices sector
- Severe 42% net income and 38.1% EPS decline raises concerns about operational execution and margin compression
- Elevated debt-to-equity ratio of 1.56x combined with profit deterioration increases financial risk and limits strategic flexibility
- ROE of 12.2% and ROA of 4.1% are suboptimal for capital intensity, suggesting inefficient capital deployment during downturn
- Flat revenue growth limits operating leverage and scale benefits
- Moderate-high leverage (Debt/Equity 1.34x) with only 5.0x interest coverage
- Profitability gains may be hard to sustain if mix/cost tailwinds fade
Key Metrics to Watch
- Quarterly revenue trends to confirm if stagnation reverses or accelerates downward
- Operating margin trajectory as management initiates cost restructuring initiatives
- Debt-to-equity ratio path—critical that leverage decreases as profitability recovers
- Free cash flow sustainability and any covenant compliance violations
- Revenue growth (YoY)
- Interest coverage
Haemonetics Corp. (HAE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.95x current ratio provides a solid financial cushion.
HAE Profit Margin, ROE & Profitability Analysis
HAE vs Healthcare Sector: How Haemonetics Corp. Compares
How Haemonetics Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Haemonetics Corp. Stock Overvalued? HAE Valuation Analysis 2026
Based on fundamental analysis, Haemonetics Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Haemonetics Corp. Balance Sheet: HAE Debt, Cash & Liquidity
HAE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Haemonetics Corp.'s revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $2.29 reflects profitable operations.
HAE Revenue Growth, EPS Growth & YoY Performance
HAE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $339.0M | $33.8M | $0.74 |
| Q2 2026 | $327.3M | $33.8M | $0.66 |
| Q1 2026 | $321.4M | $34.0M | $0.70 |
| Q3 2025 | $336.3M | $24.9M | $0.61 |
| Q2 2025 | $318.2M | $24.9M | $0.48 |
| Q1 2025 | $311.3M | $38.4M | $0.74 |
| Q3 2024 | $305.3M | $19.9M | $0.61 |
| Q2 2024 | $297.5M | $19.9M | $0.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Haemonetics Corp. Dividends, Buybacks & Capital Allocation
HAE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Haemonetics Corp. (CIK: 0000313143)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HAE
What is the AI rating for HAE?
Haemonetics Corp. (HAE) has a Combined AI Grade of B from Claude (C) and ChatGPT (A) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HAE's key strengths?
Claude: Exceptional free cash flow of $260.4M with 19.5% FCF margin demonstrates underlying business strength. Strong liquidity position with 2.95x current ratio and $245.4M cash buffer. ChatGPT: High margins with strong FCF conversion (21% FCF margin). EPS up 44.5% YoY on operating leverage and cost control.
What are the risks of investing in HAE?
Claude: Revenue stagnation at 0% YoY growth signals loss of market momentum in medical devices sector. Severe 42% net income and 38.1% EPS decline raises concerns about operational execution and margin compression. ChatGPT: Flat revenue growth limits operating leverage and scale benefits. Moderate-high leverage (Debt/Equity 1.34x) with only 5.0x interest coverage.
What is HAE's revenue and growth?
Haemonetics Corp. reported revenue of $1.3B.
Does HAE pay dividends?
Haemonetics Corp. does not currently pay dividends.
Where can I find HAE SEC filings?
Official SEC filings for Haemonetics Corp. (CIK: 0000313143) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HAE's EPS?
Haemonetics Corp. has a diluted EPS of $2.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is HAE's fundamental grade?
Based on our AI fundamental analysis in May 2026, Haemonetics Corp. has a B grade with 71% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is HAE stock overvalued or undervalued?
Valuation metrics for HAE: ROE of 12.2% (sector avg: 15%), net margin of 7.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is HAE's AI grade for 2026?
Our dual AI analysis gives Haemonetics Corp. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HAE's free cash flow?
Haemonetics Corp.'s operating cash flow is $293.2M, with capital expenditures of $32.8M. FCF margin is 19.5%.
How does HAE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 7.3% (avg: 12%), ROE 12.2% (avg: 15%), current ratio 2.95 (avg: 2).
Is Haemonetics Corp. carrying too much debt?
HAE has a debt-to-equity ratio of 1.56x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.95 suggests adequate short-term liquidity.